LIVE FROM CPHI: Molecular Profiles unveils Roadmap to Clinical Trials platform

Aims to support companies with rapid development of complex and standard drugs

UK-based contract development and manufacturing organisation Molecular Profiles, a subsidiary of Columbia Laboratories, is set to unveil its 'Roadmap to Clinical Trials' platform at CPhI to support customers with the rapid development of both standard and complex drug products.

The new enabling technologies screening platform, which incorporates the Nottingham-based company’s formulation and analytical development modules, streamlines the development of effective and bioavailable drug products.

Supported by a dedicated in-house technical team that specialises in complex research science, the new platform brings together several advanced processing capabilities including hot melt extrusion (HME), nano milling, SEDDS/SMEDDS and spray drying, allowing Molecular Profiles to investigate, evaluate and recommend a development pathway to clients that is the best option based on science.

Claire Madden-Smith: We aim to provide a robust streamlined pathway to clinic

Claire Madden-Smith, Commercial Director at Molecular Profiles, explained: 'There are critical decisions that clients can now make at an early stage in the drug development process, which can have major, longer-term consequences for their compounds.

'The idea behind our Roadmap to Clinical Trials platform is to provide a robust streamlined pathway to clinic. Even for challenging product development we have introduced a screening process which can provide strong scientific evidence based on in-vitro and in-vivo data to help progress to formulation optimisation in less than eight weeks.

Madden-Smith added: 'Ultimately, it’s about rapidly assisting clients to choose a development pathway that will be the most time, cost and volume efficient route for their valuable product.'

Companies